GROUP ONE TRADING, L.P. - BLUEPRINT MEDICINES CORP ownership

BLUEPRINT MEDICINES CORP's ticker is and the CUSIP is 09627Y959. A total of 5 filers reported holding BLUEPRINT MEDICINES CORP in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
GROUP ONE TRADING, L.P. ownership history of BLUEPRINT MEDICINES CORP
ValueSharesWeighting
Q3 2023$5,217,858
-15.1%
103,900
+6.9%
0.02%
-10.0%
Q2 2023$6,143,040
+186.3%
97,200
+103.8%
0.02%
+150.0%
Q1 2023$2,146,023
+61.1%
47,700
+56.9%
0.01%
+166.7%
Q4 2022$1,331,824
+24.8%
30,400
+87.7%
0.00%
+50.0%
Q3 2022$1,067,000
+2948.6%
16,200
+2214.3%
0.00%
Q2 2022$35,000
-97.9%
700
-95.5%
0.00%
-100.0%
Q4 2021$1,649,000
-1.6%
15,400
-5.5%
0.00%
-50.0%
Q3 2021$1,676,000
-2.8%
16,300
-16.8%
0.00%0.0%
Q2 2021$1,724,000
+1859.1%
19,600
+2077.8%
0.00%
Q1 2021$88,000
-95.0%
900
-94.3%
0.00%
-100.0%
Q4 2020$1,761,000
-23.4%
15,700
-36.7%
0.00%
-57.1%
Q3 2020$2,299,000
-8.7%
24,800
-23.2%
0.01%
-41.7%
Q2 2020$2,519,000
+85.6%
32,300
+39.2%
0.01%
+9.1%
Q1 2020$1,357,000
-33.3%
23,200
-8.7%
0.01%
-21.4%
Q4 2019$2,035,000
+102.1%
25,400
+85.4%
0.01%
+75.0%
Q3 2019$1,007,000
+11088.9%
13,700
+13600.0%
0.01%
Q2 2019$9,000
-98.4%
100
-99.0%
0.00%
-100.0%
Q4 2018$561,000
-51.8%
10,400
-30.2%
0.01%
-44.4%
Q3 2018$1,163,000
+22.2%
14,900
-0.7%
0.01%
+12.5%
Q2 2018$952,000
+10477.8%
15,000
+14900.0%
0.01%
Q1 2018$9,000
-89.2%
100
-90.9%
0.00%
-100.0%
Q4 2017$83,000
-1.2%
1,100
-47.6%
0.00%0.0%
Q1 2017$84,000
+9.1%
2,100
-19.2%
0.00%0.0%
Q3 2016$77,000
+140.6%
2,600
+62.5%
0.00%
Q2 2016$32,000
-25.6%
1,600
-33.3%
0.00%
-100.0%
Q1 2016$43,000
-31.7%
2,4000.0%0.00%0.0%
Q4 2015$63,0002,4000.00%
Other shareholders
BLUEPRINT MEDICINES CORP shareholders Q2 2022
NameSharesValueWeighting ↓
PURA VIDA INVESTMENTS, LLC 10,000$505,0000.03%
CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0$00.00%
GROUP ONE TRADING, L.P. 700$35,0000.00%
JANE STREET GROUP, LLC 13,200$667,0000.00%
SIMPLEX TRADING, LLC 100$5,0000.00%
View complete list of BLUEPRINT MEDICINES CORP shareholders